[{"from": "human", "value": "Provide a description of this molecule. [C][O][C][=C][Branch2][=Branch1][N][C][=C][C][N][Branch1][=Branch2][C][C][C][Ring1][=Branch1][=C][Ring1][#Branch2][C][C][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][N][=C][Branch1][Branch1][N][=N][Ring1][Branch1][C][=C][C][=Branch2][Ring1][P][=C][Branch2][Ring1][O][C][=C][Ring1][=Branch1][N][C][=Branch1][C][=O][C][=C][C][=Branch1][C][=O][C][=C][C][=C][C][=C][Ring1][=Branch1][O][Ring1][O][O][C][O][C][O][C].[C][S][=Branch1][C][=O][=Branch1][C][=O][O]"}, {"from": "gpt", "value": "The molecule is the mesylate form of encequidar, an inhibitor of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter P-glycoprotein (P-gp), with adjuvant activity. Upon oral administration, encequidar selectively binds to and inhibits the multidrug resistance (MDR) efflux pump P-gp, which prevents the efflux of various chemotherapeutic agents from intestinal epithelial cells to the gastrointestinal tract. This leads to an increase in both oral bioavailability and therapeutic efficacy. P-gp prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents. Encequidar is not systemically absorbed."}]